< Back to previous page
Project
The role of autoreactive T cells and IgE autoantibodies in atopic dermatitis; From bench to bedside and back (FWOAL1034)
In patients with atopic dermatitis (AD), increased risk of co-morbid
autoimmune diseases was found. Additionally, IgE-mediated
autoimmunity directed to the skin has been demonstrated in patients
with moderate/severe AD, suggesting a role for autoreactive IgE
antibodies and self-reactive T cells in AD pathophysiology and an
association with disease severity. Previously, we measured IgEautoreactivity in serum samples using a newly established
immunoassay. In the present project, we hypothesize that
autoreactive IgE antibodies can be present or develop already shortly
after birth, and that IgE autoantibodies levels correlate with disease
activity. The project aims at investigating the very first stages of IgEmediated autoimmunity in new-borns in relation to AD-development,
heredity and environmental exposure. Next, we aim to explore the
effect of systemic treatment on autoreactive IgE antibody levels and
to evaluate the relation with disease activity. Finally, we presume that
modulation of the PD-1/PD-L1 axis could be a potential target for
therapy in these patients. Ultimately, we aim to modulate the PD1/PD-L1 axis as novel target for therapy in a mouse model. This
project will increase current insights of AD-pathophysiology with IgEmediated autoimmunity and open new doors for disease endotyping
and precision therapy with direct consequences for diagnosis and
treatment of patients with AD and IgE autoimmunity..
autoimmune diseases was found. Additionally, IgE-mediated
autoimmunity directed to the skin has been demonstrated in patients
with moderate/severe AD, suggesting a role for autoreactive IgE
antibodies and self-reactive T cells in AD pathophysiology and an
association with disease severity. Previously, we measured IgEautoreactivity in serum samples using a newly established
immunoassay. In the present project, we hypothesize that
autoreactive IgE antibodies can be present or develop already shortly
after birth, and that IgE autoantibodies levels correlate with disease
activity. The project aims at investigating the very first stages of IgEmediated autoimmunity in new-borns in relation to AD-development,
heredity and environmental exposure. Next, we aim to explore the
effect of systemic treatment on autoreactive IgE antibody levels and
to evaluate the relation with disease activity. Finally, we presume that
modulation of the PD-1/PD-L1 axis could be a potential target for
therapy in these patients. Ultimately, we aim to modulate the PD1/PD-L1 axis as novel target for therapy in a mouse model. This
project will increase current insights of AD-pathophysiology with IgEmediated autoimmunity and open new doors for disease endotyping
and precision therapy with direct consequences for diagnosis and
treatment of patients with AD and IgE autoimmunity..
Date:1 Jan 2022 → Today
Keywords:Atopic dermatitis, autoimmunity, autoreactive immunoglobulin E antibodies
Disciplines:Autoimmunity, Adaptive immunology, Dermatology, Inflammation, Innate immunity